Efficacy and safety of oxcarbazepine in bipolar disorder [1]

Canadian Journal of Psychiatry

Volumn 52, Issue 4, 2007, Pages 272-

  Mazza, Marianna ^a   Bria, Pietro ^a   Mazza, Salvatore ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; HALOPERIDOL; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OXCARBAZEPINE; PLACEBO;

ADD ON THERAPY; BIPOLAR DISORDER; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; HYPONATREMIA; LETTER; MANIA; MONOTHERAPY; OUTCOME ASSESSMENT; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS;

EID: 34248349159     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370705200414     Document Type: Letter

References (5)

1. Pratoomsri W, Yatham LN, Bond DJ, et al. Oxcarbazepine in the treatment of bipolar disorder: a review. Can J Psychiatry. 2006;51:540-545.
2. Emrich HM. Studies with oxcarbazepine (Trileptal) in acute mania. Int Clin Psychopharmacol. 1990;5(Suppl 1):83-88.
3. Jefferson JW. Oxcarbazepine in bipolar disorder. Primary Care Companion J Clin Psychiatry. 2001;3(4):181.
4. Hummel B, Walden J, Stampfer R, et al. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disorders. 2002;4:412-417.
5. Wagner KD, Kowatch RA, Emslie GJ, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry. 2006;163:1179-1186.